Nouscom is a next-generation immunotherapy company developing engineered viral vectored vaccines for the treatment of cancer.

Nouscom

Nouscom is a private oncology company developing next generation immunotherapies. Nouscom’s proprietary technology platform, Exovax, harnesses the full power of immune response by combining viral vectored genetic vaccines based on neoantigens with other immunomodulators.
 
Nouscom is led by an experienced management team that has worked together for many years in previous successful enterprises, including IRBM/Merck and Okairos (acquired by GSK), and are veterans in the field of genetic vaccines.
 
Nouscom, which was founded in 2015 and is headquartered in Basel, Switzerland with operations in Rome, Italy, is backed by international life sciences investors: 5AM, Abingworth, LSP (Life Sciences Partners) and Versant Ventures.
 
For more information on Nouscom, please visit the company’s website at www.nouscom.com

Versant Ventures

EQT life science

LSP BioVentures

5AM Ventures

Abingworth

Nouscom AG

We are excited to attend the #JefferiesHealthcare conference June 7-9 in New York City where our CEO Marina Udier-Blagovic will present on Thursday at 8 am in Track 10. Nouscom AG is a clinical stage biotech developing off-the-shelf and personalized cancer vaccines. It uses a proprietary viral vector platform with capacity to encode for large number of neoantigens to safely and potently harness the power of the immune system. 6 clinical trials are actively ongoing, including a randomized Phase 2 trial of #NOUS-209 for the treatment of MSI-H solid tumors in combination with pembrolizumab, as well as #NOUS-PEV, a personalized cancer vaccines that reported Phase 1 data at American Association for Cancer Research 2023. Nouscom’s cancer vaccines induce potent and durable CD8 T cells, which are recruited to the tumor where they expand, diversify and drive tumor killing (D’Alise et al, #ScienceTranslationalMedicine 2022).

Nouscom is excited to attend the 9th Immuno-Oncology Innovation Forum #Sachs_IOIF on June 2 in Chicago where our CEO Marina Udier-Blagovic will join the panel discussing the future of neoantigen cancer vaccines. Nouscom’s proprietary platform based on viral vectors induces potent and durable CD8 T cell responses. These responses translate into clinical benefit for metastatic cancer patients, as demonstrated in multiple clinical trials (#NOUS-209, #NOUS-PEV released at American Association for Cancer Research 2023, Society for Immunotherapy of Cancer (SITC) 2022, American Society of Clinical Oncology (ASCO) 2022). CD8 T cells induced by the vaccine are recruited to the tumor where they proliferate and drive tumor killing (D’Alise et al,  #ScienceTranslationalMedicine 2022).

Nouscom announces the publication of a new manuscript on JITC, titled “Vector Aided Microenvironment programming (VAMP): reprogramming the TME with MVA virus expressing IL-12 for effective antitumor activity”, describing how Nouscom’s MVA encoding IL-12 is highly effective in preclinical tumor models resistant to the activity of checkpoint inhibitors, supporting its use as novel and more safe strategy to overcome TME mediated resistance to immunotherapy. 
https://lnkd.in/eb733NaV
#immunotherapy #nouscomag #viralvectors

Today we are presenting new positive translational Phase 1b data of NOUS-PEV, our personalized neoantigen cancer immunotherapy, in a late-breaking abstract session at the 2023 American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida. 
 
The session entitled ‘Late-Breaking Research: Clinical Research 2’ will take place at 9:00 AM – 12:30 PM EDT. 
 
Find out more: https://lnkd.in/eEsTadK8
 
View the full abstract: https://lnkd.in/eCHzg9p5 
 
#NOUSPEV #oncology #AACR23

We will be presenting a Late-breaking abstract at the 2023 American Association for Cancer Research Annual Meeting on 18th April 2023, 9:00 am - 12:30 pm EDT in Orlando, Florida. 
 
The abstract will reveal new translational data from the ongoing Phase 1b trial evaluating NOUS-PEV in patients with metastatic melanoma. 
 
For more details: https://lnkd.in/eKWBQeJS
 
#NOUSPEV #oncology #AACR23

Today is International Women's Day 2023, a global day to celebrate the social, economic, cultural and political achievements of women. At Nouscom, we are proud to support equal opportunities for women in the biotech industry, with 85% of our employees being female. Further, we are delighted to announce the following promotions of 3 of our female employees: 
·      Loredana Siani to Vice President, Technical and CMC Development 
·      Tiffany Brooke Muller to Senior Vice President, Finance 
·      Morena D’Alise to Vice President, Immunology 
 
Find out more about the global movement in which this year’s theme is #EmbraceEquity and marks a call to action to accelerate women’s equality: https://lnkd.in/dGX7T8X 
  
#IWD23

Join us in welcoming Sarah Runswick as our Senior Director, Clinical Science.
She is an experienced global clinical scientist with over 20 years expertise in early and late stage Oncology Clinical trial development and delivery, including successful regulatory submission experience and leading investigator study strategy programs.
https://lnkd.in/exiBD5Rz

#people #biotech #immunotherapy

March is Colorectal Cancer Awareness month. 
 
Colorectal cancer is the second deadliest cancer in Europe and the US. Colorectal cancer can be prevented by identifying and removing polyps early before developing into cancer. At Nouscom, we want to raise awareness of colorectal cancer and encourage regular screening to identify colorectal polyps or cancer earlier to allow the best chances of successful treatment. 
 
Find out more about Colorectal Cancer Awareness Month: https://lnkd.in/dMSUMKg 

#colorectalcancer #oncology #cancerawareness

Join us in welcoming Yen-Ching Chua as our Vice President, Clinical Operations. 
She is an experienced global clinical operations leader with over 20 years expertise in leading Pharmaceutical Development Operations 
including Quality Assurance and Pharmacovigilance.
https://lnkd.in/eAiqTxQU

#people #biotech #immunotherapy

We are delighted to announce the first patient has been dosed in the Phase 2 trial evaluating our lead product, NOUS-209, an ‘off-the shelf’ neoantigen cancer immunotherapy in dMMR/MSI-High metastatic colorectal cancer. 
 
Read the full PR here: https://lnkd.in/eTCtSbJw
 
#oncology #clinicaltrial #immunotherapy

CloudFront

ASP.NET

IIS 10

Microsoft

ASP.NET 4.0

GoDaddy SSL

SiteGround CAPTCHA

Dutch Server Location

Senior Vice President Finance

Tiffany Muller

Engineering

Chiara Felici

Vice President/Global Head of Regulatory Affairs

Maria Arce-Tomas

Business Management

Rosa Vitale

Paolo Di Giorgio

Scott M. Rocklage

Sofia Ioannidou

Guido Magni

Hakan Goker

Thibaut Roulon

Marina Udier

Loredana Siani

Technical Director for Development

Cinzia Traboni

Senior Director of regulatory affairs & Co- Founder

Patricia Delaite

Elisa Scarduelli

Chief Scientific Officer & Co-Founder

Senior Vice President, Technical and CMC Development

Göran Ando

MD & Chairman

Chief Financial Officer

Health Care Companies With Fewer Than 1000 Employees (Top 10K)

Switzerland Companies With Fewer Than 100 Employees (Top 10K)

Europe, Middle East, and Africa (EMEA) Late Stage Companies With More Than $1M in Revenue

Health Care Companies With More Than 10 Employees (Top 10K)

Nouscom is a developer of an immunotherapy platform that aims to create modified viral vector vaccines for cancer treatment. The company's platform makes use of a portfolio of engineered viral vectors that have been optimized for the efficient expression of long strings of tumor neoantigens. It also includes a toolkit for inducing broad and potent antitumor T-cell responses, allowing patients to boost cancer-specific cellular immunity.

Angelini Ventures

Series C - Nouscom

Andera Partners

Bpifrance

M Ventures

Series B - Nouscom

EQT Life Sciences

Series A - Nouscom

Basel

Basel-Stadt

Switzerland

Europe

Nouscom Completes Patient Enrollment of Randomized Phase 2 Study Evaluating NOUS-209, an Off-the-Shelf Neoantigen Immunotherapy, in dMMR/MSI Metastatic Colorectal Cancer

Nouscom’s Off-the-Shelf Neoantigen Immunotherapy, NOUS-209, Continues to Elicit Potent and Durable Immune Responses in Lynch Syndrome Carriers Highlighting its Potential to ‘Intercept’ Cancer

Biotech companies report progress in clinical trials

Nouscom Appoints Tiffany Muller as Chief Financial Officer

Nouscom–Muller T: management, 202407– promoted to CFO joined 2019 as VP Finance before Aramark

Nouscom Appoints Tiffany Muller as Chief Financial Officer and Loredana Siani as Senior Vice President, Technical and CMC Development

Nouscom Appoints Leading Cancer Drug Development Expert, Neil Gallagher, MD, PhD, as Independent Advisor to its ...

A personalized cancer vaccine targeting individual patient tumor neoantigens for various cancer types.

An off-the-shelf cancer immunotherapy targeting tumors with mismatch repair deficiency and microsatellite instability by encoding 209 unique frame shift peptide cancer neoantigens.

A personalized cancer vaccine tailored to individual patient tumor mutanomes, encoding up to 60 unique neoantigens selected using the VENUS algorithm.

An off-the-shelf cancer immunotherapy targeting neoantigens common in dMMR/MSI tumors.

An oncolytic virus therapy designed to selectively infect and kill cancer cells while stimulating an immune response.

An oncolytic Herpes Virus engineered to selectively infect and kill cancer cells, while expressing immunomodulatory molecules to enhance anti-tumor immune responses.

news impact assignment basic	general	Oct 5, 2024 2:18 PM	1ec87bc2
public peers	general	Oct 2, 2024 11:39 AM	2cbbcac8
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Oct 4, 2024 8:20 AM	de3c3041
company summary	general
signals	general	Oct 2, 2024 11:39 AM	aaa61bd9
crunchbase trigger	general	Nov 22, 2024 7:44 AM	6acf9d6f
crunchbase profile	general	Nov 22, 2024 8:46 AM	d2ca14e7
li profile	general
translate crunchbase fundingrounds	general	Nov 22, 2024 10:58 AM	82d7a463
peers	general	Oct 2, 2024 11:39 AM	3a55ccd7
news basic	general	Oct 2, 2024 11:39 AM	74e9c2f8
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:NOUSCOM

Nouscom